High drug costs are systemic, rooted in the for-profit model's legal obligation to prioritize shareholder returns over patient affordability. This is compounded by a complex distribution chain where multiple middlemen—wholesalers, insurers, and pharmacies—each add a profit layer, inflating the final price.

While AI enables rapid drug creation for single individuals (n-of-1), the economic model is broken. It is not a commercial opportunity, creating an urgent societal challenge to develop new funding mechanisms like public-private partnerships to support these life-saving, non-scalable treatments.

For gene editing to achieve its potential, companies must solve an economic problem, not just a scientific one. The key is developing a manufacturing system that dramatically lowers costs, making one-time cures for the "long tail" of rare mutations financially viable and accessible.

Aphaia's drug formulation is built around glucose, one of the most abundant and inexpensive materials on Earth. This deliberate strategic choice contrasts with complex, expensive injectables. It positions their treatment to address the 94-97% of eligible patients worldwide who cannot access or afford current therapies, creating a massive market opportunity.

An outsider's perspective, free from industry dogma, can be a powerful asset in life sciences. This viewpoint enables questioning of established norms and identifying unconventional solutions, such as applying a non-profit fundraising model to drug manufacturing.

The surge in use of compounded GLP-1s, costing about half the price of branded versions, demonstrates huge untapped demand. Patients are willing to accept manufacturing and safety risks for affordability, proving price is a major barrier to adoption.

Mark Cuban reveals the primary barrier to making generic drugs in the US isn't production cost, which can be cheaper than overseas, but the prohibitive FDA application fees costing hundreds of thousands per drug.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

A great molecule isn't enough to attract investment. Scientists must demonstrate they've considered manufacturing from day one. Designing a robust process that fits a consistent GMP facility shows investors that the project is not just a scientific curiosity but a viable path to a scalable product.